Back to Screener

Tevogen Bio Holdings Inc. Warrant (TVGNW)

Price$0.04

Favorite Metrics

Price vs S&P 500 (26W)-33.15%
Price vs S&P 500 (4W)-7.05%

All Metrics

Price vs S&P 500 (YTD)-13.41%
10-Day Avg Trading Volume0.15M
3-Month Avg Trading Volume0.14M
52-Week High$0.08
26-Week Price Return-24.40%
13-Week Price Return-15.44%
3-Month Return Std Dev84.50%
Year-to-Date Return-10.43%
5-Day Price Return18.87%
Month-to-Date Return11.50%
Price vs S&P 500 (13W)-18.30%
Beta0.07x
52-Week Low$0.03

Industry Peers — Biological Products(89)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
TVGNWTevogen Bio Holdings Inc. Warrant
$0.04
AMGNAmgen Inc
5.20x9.95%73.30%2.93%$350.16
GILDGilead Sciences Inc
5.71x2.40%78.83%133.64%$135.87
ARGXargenx SE American Depositary Shares
12.59x89.56%150.91%$834.45
BNTXBioNTech SE American Depositary Share
9.06x-11.81%84.21%$105.19
BIIBBiogen Inc. Common Stock
2.72x2.22%75.69%-18.77%$183.34
MRNAModerna, Inc. Common Stock
10.91x-39.93%70.32%$54.59
NBIXNeurocrine Biosciences Inc
4.64x21.45%98.18%2.31%$131.59
EXELExelixis Inc
4.89x6.85%96.39%31.10%$43.61
TECHBio-Techne Corp.
7.72x1.64%66.60%-20.58%$60.58
IBRXImmunityBio, Inc. Common Stock
74.42x668.31%99.34%$8.20

About

Tevogen Bio Holdings Inc is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies designed to harness the immune system's ability to fight disease. The company's platform leverages CD8+ cytotoxic T lymphocytes to create precision cell therapies with the potential to treat infectious diseases, cancers, and neurological disorders. By focusing on ready-to-use cell therapies rather than patient-specific treatments, Tevogen aims to improve accessibility and scalability in the immunotherapy market.